IRIC - Institute for Research in Immunology and Cancer

A forum for Gender Equality Week in Canada

As an institution, IRIC seeks to promote equity and increase diversity and inclusion, in all of its forms, throughout its programs.

Lecture by Dr. Tomas Lindahl - Nobel Prize in Chemistry in 2015

November 29, 2021

IRIC will welcome Dr. Tomas Lindahl, Nobel Prize in Chemistry in 2015, on Monday, November 29, 2021.

The online lecture, titled “Mutagenic Causes of Cancer”, will start at 11:30 am and be followed by a meeting with Dr. Lindahl.

Geneviève Deblois, lecturer at Les Belles Heures de l’Université de Montréal

November 29, 2021

Please note that the conference will be in French only.

For more details: https://www.iric.ca/fr/a-propos/evenements/genevieve-deblois-conferenciere-aux-belles-heures-de-luniversite-de-montreal

Distinguished Scientist Lecture Series - Fall 2021

September 13—December 6, 2021

IRIC presents the 32nd edition of its Distinguished Scientist Lecture Series, with a full ten part program.

Join us on Mondays at 11:30 am, to learn about the latest findings in cancer research with leading biomedical investigators from Canada, USA and Europe.

Pierre Thibault’s team shares its knowledge on mass spectrometry-based proteomic strategies used to study UBL like modifications

The group of Pierre Thibault, Principal Investigator at IRIC and professor in the Department of Chemistry of UdeM, with a colleague from Leiden University Medical Center in the Netherlands, recently published an exhaustive review article in Nature Reviews Methods Primers to educate researchers of all levels on the variety of mass spectrometry-based proteomic strategies used to study ubiquitin-like (UBL) modifications and the type of information that can be generated through these approaches.

Brian Wilhelm awarded with major funding through the new Genomics Integration Program – Human Health initiated by Génome Québec

Brian Wilhelm, Principal Investigator at IRIC and Associate Professor in the Department of Medicine at the Faculty of Medicine of the Université de Montréal, is the recipient of major funding through the new Genomics Integration Program – Human Health, initiated by Génome Québec in collaboration with the Oncopole.

IRIC salutes the Quebec government for its commitment: $13M invested to bring together the players in the drug discovery and production field

IRIC is delighted by the creation of “Médicament Québec”, a major strategic hub whose mission is to promote greater autonomy and increase Quebec’s drive with respect to drug discovery, development and production.

Appointment of Clarissa Desjardins and renewal of Robert Paré and Jacques Bernier’s mandate on the IRIC’s Board of Directors

IRIC is pleased to announce the appointment of Dr. Clarissa Desjardins as a new member of the Board of Directors as well as the renewal of Mtre Robert Paré and Mr. Jacques Bernier’s mandate as a member of the Board by the Executive Committee of the Université de Montréal.

Fonds vaccin thérapeutique contre le cancer: Donations that make a real difference

In early 2020, IRIC created its brand new “Fonds vaccin thérapeutique contre le cancer”, a fund initiated by Dr. Robert Patenaude with a personal contribution of $25,000. The objective was to support the scientists involved in the project, namely the team led by Dr. Claude Perreault, in collaboration with the teams led by Sébastien Lemieux and Pierre Thibault, who work tirelessly to change the life of people affected by cancer.

Fondation Marcel et Rolande Gosselin: A major donation renewal for IRIC’s chemolibrary

Convinced that IRIC’s model contributes to achieving the mission of the Fondation Marcel et Rolande Gosselin, and excited about the recent advances generated by the Institute’s research teams, the Trustees of the Fondation Marcel et Rolande Gosselin announce a $500,000 donation renewal for IRIC’s chemolibrary.

Aubry-Bouvier donations: An exceptional legacy to support the next generation of scientists

Because the next generation of scientists means so much to them, IRIC’s Chief Executive Officer, Mr. Michel Bouvier, and his partner, Ms. Muriel Aubry, retired Professor and Director of the Department of Biochemistry and Molecular Medicine at the Université de Montréal, are pleased to announce the creation of two endowed funds to support students.

IRIC participates in the next Forum of the Chamber of Commerce of Metropolitan Montreal

On Monday, May 31, IRIC will take part in the Strategic Forum Universities, CEGEPs, businesses: Working together for a strong, innovative and socially responsible economy, an initiative co-developed by the Chamber of Commerce of Metropolitan Montreal and the FRQs.

Trang Hoang is the recipient of the 2021 CSMB Jeanne Manery Fisher Award

Trang Hoang, Principal Investigator at the Institute for Research in Immunology and Cancer (IRIC) and Full Professor in the Department of Pharmacology at the Faculty of Medicine of the Université de Montréal is the recipient of the 2021 Canadian Society for Molecular Biosciences (CSMB) Jeanne Manery Fisher Award.

Les Rendez-vous Audace 2021: $320,000 raised to support IRIC’s cancer research efforts

Exceptionally this year, the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal presented a virtual formula of its traditional Audacious fundraising event: Les Rendez-vous Audace. For the occasion, approximately 615 people from 8 countries attended the three free conferences and close to 20 sponsors supported the event. Thanks to the generosity of our partners and donors, a total of $320,000 was raised to accelerate the discovery of better therapies for the benefit of patients.

Genome-wide screens identify a novel gene that tapers the DNA damage response in human cells with eroded telomeres

Telomeres are DNA sequences that serve as critical caps to protect the ends of chromosomes against degradation, fraying, and fusion with other chromosomes. They play an important role in maintaining genome integrity but in most cells in our body, telomeres become shorter with each cell division as the activity of the telomere maintenance enzyme (TERT) is repressed. After sufficient telomere shortening, the protective telomere structure is lost, activating the tumor-suppressor gene p53 and the DNA damage response. This leads to a non-proliferative state in normal cells called senescence, or to cell death in cancer cells. These inhibitory effects upon cell proliferation are thought to be an important mechanism to prevent the proliferation of damaged cells and the formation of tumors.